The present study consists of a retrospective multicentric collection of all consecutive patients with PMBCL diagnosed over the time period considered (13 years, from 2007 to 2019 inclusive).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Rate of primary/early refractory disease
Timeframe: The endpoint will be evaluated from the beginning to the end of the study (up to 24 months)
Overall response rate (ORR)
Timeframe: The endpoint will be evaluated from the beginning to the end of the study (up to 24 months)
Complete response rate (CRR)
Timeframe: The endpoint will be evaluated from the beginning to the end of the study (up to 24 months)
Frequency of administration of mediastinal radiation therapy
Timeframe: four months after completion of chemotherapy
Progression Free Survival (PFS)
Timeframe: The endpoint will be evaluated from the beginning to the end of the study (up to 24 months)
Overall Survival (OS)
Timeframe: The endpoint will be evaluated from the beginning to the end of the study (up to 24 months)